In the 5 patients with bilateral geographic atrophy (GA) who received a K8 implant in 1 eye, there was a mean reduction in GA ...

OCU400 demonstrated meaningful improvement of 2-line gain (10 letters on ETDRS chart) in low-luminance visual acuity (LLVA) in treated eyes when compared to untreated fellow eyes. Ocugen, Inc.

City Therapeutics, Inc. set to collaborate with Bausch + Lomb on the development of a novel therapy for the treatment of retinal diseases including geographic atrophy (GA). The arrangement of this ...

In a press release, Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., announced it would partner with Klinge Biopharma GmbH and Formycon AG in ...

UNITY believes that its lead candidate, UBX1325 (foselutoclax), with its unique mechanism of action, has the potential to improve long-term visual outcomes in DME patients by addressing treatment ...